ERBB2 and breast carcinoma: Breast cancer patients can be successfully treated with the humanised monoclonal antibody trastuzumab (Herceptin, Hoffman-La Roche Ltd, Basel, Switzerland) (Pegram et al, 1998), and therefore accurate evaluation of HER2 status is essential for better management.